Cannara Announces DTC Eligibility to Facilitate U.S. Investor Access and Strengthens Balance Sheet through completion of Debt-to-Equity Conversion

Core Insights - Cannara Biotech Inc. has achieved DTC eligibility for its common shares, enhancing trading liquidity and access for U.S. investors [1][2][3] - The company completed the issuance of 3,462,763 common shares to Olymbec Investments Inc. to settle approximately $6.2 million in debt, which includes $4.7 million in principal and $1.5 million in accrued interest [3][4] - The DTC eligibility is expected to broaden Cannara's shareholder base and increase visibility in the U.S. market, particularly in light of potential federal regulatory reforms in the cannabis industry [3][4] Company Overview - Cannara Biotech Inc. is a vertically integrated producer of premium-grade cannabis products, operating two mega facilities in Québec with a total area of over 1,650,000 sq. ft. [1][7] - The company has a potential annual cultivation output of 100,000 kg, leveraging low electricity costs in Québec to produce affordable cannabis products [7] Financial Strategy - The completion of the Olymbec share issuance is aimed at reducing debt leverage and interest obligations, thereby preserving liquidity for long-term growth strategies [4] - The transaction is anticipated to strengthen Cannara's balance sheet and enhance financial flexibility [4]